MindMed Inc.

NEO: MMED, OTCQB:MMEDF, DE: BGHM

Company Logo

Company Overview

Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.

The company’s immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. In addition, the company has established a microdosing division to conduct clinical trials of LSD microdosing for Adult ADHD, is pursuing experiential psychedelic assisted therapy for the treatment of anxiety, and is collaborating on a clinical trial to evaluate LSD for the treatment of cluster cluster headaches.

The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. 

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

$0.00

Diluted EPS (ttm)

Management Team

Mr. Jamon Alexander Rahn
Co-Founder, CEO & Director

Dr. Miri Halperin Wernli
Pres, Head of Clinical & Director

Dr. Scott M. Freeman
Co-Founder & Clinical Advisor

Mr. Leonard Latchman
Co-founder

Mr. David Dean Guebert
Chief Financial Officer

Ms. Carol Nast
Chief Operating Officer

Dr. Donald R. Gehlert Ph.D.
Chief Scientific Officer & Member of Scientific Advisory Board

Ms. Madeline Feldman
Director of Operations & Admin.

Mr. Collin Gage
Head of Corp. Devel.

Ms. Jeanne Bonelle
Exec. VP of Technical Operations

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$742,544,021

Shares Outstanding
225,697,271

Shares Short (% of Float)
0 (0%)

Insider Ownership
0%